New Study Associates Blood Glucose Monitoring With Lower A1C Levels and Greater Medication Adherence in Type 2 Diabetes Patients Who Don’t Use Insulin
MILPITAS, Calif., Oct. 16, 2012 /PRNewswire/ — A new study suggests that blood glucose monitoring is associated with reduced A1C levels and greater adherence to medication in type 2 diabetes patients who do not take insulin. The study is published online in Diabetes Technology & Therapeutics and appeared in the publication’s September print issue.
The preliminary study findings were based on a retrospective analysis of health insurance data and was led by Dr. Naunihal Virdi, Medical Affairs at LifeScan, Inc. The results are based on an analysis of 4.5 years of data gathered from 5,172 patients with type 2 diabetes who were newly treated with non-insulin diabetes medication. Patients who tested their blood glucose showed a greater overall decrease in A1C than those not testing (-1.4 vs. -0.6 A1C percentage points respectively). Overall, higher blood glucose testing frequency was associated with greater decreases in A1C levels. Patients who tested at least once per day had the greatest reductions in A1C levels compared with patients who tested less frequently, or not at all.
This study also found that patients who tested their blood glucose were more likely to take their diabetes medication as prescribed than patients who didn’t test (49.9% vs. 38.2%, respectively). Again, testing frequency was a factor, with 64.1% of patients who tested at least once a day being adherent to their medications compared to less than 50% of those testing less frequently.
“Good glycemic control is key to reducing complications in patients with diabetes,” said Dr. Virdi. “For type 2 patients who don’t take insulin, this study adds to the growing body of evidence that regular self-monitoring of blood sugar may contribute to improved diabetes control as well as improved compliance in taking medications as prescribed.”
The study findings were based on a retrospective analysis of health insurance data and are considered by the authors as preliminary to other studies that may confirm these findings via a prospective clinical trial. A link to the abstract of the study may be viewed at: http://online.liebertpub.com/doi/abs/10.1089/dia.2012.0047
About the Johnson & Johnson Diabetes Care Franchise:
Four operating companies comprise the Johnson & Johnson Diabetes Care Franchise with the shared vision of “Creating a world without limits for people with diabetes.” Providing advanced products and services, professional and community education, and advocacy and support to people living with diabetes and their families, these companies include: LifeScan, Inc., (www.OneTouch.com) a world leader in blood glucose monitoring; Animas Corporation, (www.Animas.com) maker of innovative insulin delivery systems; Children with Diabetes, Inc., (www.childrenwithdiabetes.com) a community offering support and education for children, adults and their families living with diabetes; and the Johnson & Johnson Diabetes Institute, LLC, (www.JJDI.com) that empowers healthcare professionals with education and training programs to improve the quality of life for people with diabetes.
SOURCE LifeScan, Inc.